trending Market Intelligence /marketintelligence/en/news-insights/trending/s614wORW7UHlZ0OqlJ-JrA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sanofi prices €2B debt offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sanofi prices €2B debt offering

Sanofi has priced a €2 billion debt offering, with net proceeds to be used for general corporate purposes.

The French pharmaceutical giant is offering €850 million of zero percent fixed-rate notes due March 2022, €650 million of 0.875% fixed-rate notes due March 2029 and €500 million of 1.25% fixed-rate notes due March 2034.

Sanofi said the notes, being issued under a euro medium-term note program, will help the company lower its average cost of debt and extend the average maturity of the debt.

Bank of America Merrill Lynch and Natixis are serving as global coordinators and book runners. ING and Santander are also serving as book runners for the offering.